Investments in progress
We are out there looking for the next big thing or at the office analyzing, verifying the facts, and drafting agreements. Sign up and we will let you know once have found something great.
Our portfolio companies
Our portfolio companies are currently developing diagnostics for early detection of cancer via blood sample, saving lives in emergency care and surgery through software innovations, developing personalised treatments of severe diseases, and much more.
Single Technologies
The company has developed a DNA sequencing solution with significantly improved performance compared with current alternatives. The market is growing rapidly in terms of both research and clinical applications.
EMPE Diagnostics
Each year, more than 10 million people suffer from tuberculosis. EMPE has developed a patented quick test for the diagnosis of tuberculosis adapted to clinics with limited resources.
Predicare
Predicare is the company behind the system RETTS©, used by 95% of Sweden’s hospitals and ambulances. RETTS© daily helps healthcare professionals to make the right decisions in emergency situations.
Exits
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.
Lipigon Pharmaceuticals
Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.
Read more
Inhalation Sciences
Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.
Read more